Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials

Deborah Hinnen,1 Davida F Kruger2 1Department of Health and Wellness, Memorial Hospital Diabetes Center, University of Colorado Health, Colorado Springs, CO 80909, USA; 2Henry Ford Health System, Division of Endocrinology, Diabetes, Bone and Mineral Disease, Henry Ford Medical Center – New...

Full description

Bibliographic Details
Main Authors: Hinnen D, Kruger DF
Format: Article
Language:English
Published: Dove Medical Press 2019-04-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
Online Access:https://www.dovepress.com/cardiovascular-risks-in-type-2-diabetes-and-the-interpretation-of-card-peer-reviewed-article-DMSO
_version_ 1797717983248777216
author Hinnen D
Kruger DF
author_facet Hinnen D
Kruger DF
author_sort Hinnen D
collection DOAJ
description Deborah Hinnen,1 Davida F Kruger2 1Department of Health and Wellness, Memorial Hospital Diabetes Center, University of Colorado Health, Colorado Springs, CO 80909, USA; 2Henry Ford Health System, Division of Endocrinology, Diabetes, Bone and Mineral Disease, Henry Ford Medical Center – New Center One, Detroit, MI 48202, USA Background: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is paramount to determine the relationship between these two diseases. Purpose: Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug Administration published guidance for manufacturers on antihyperglycemic agents, requiring studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents have conducted and published results from CV outcomes trials (CVOTs), with more trials due to publish soon. This review discusses the relationship between CVD and T2D and explores findings from the latest CVOTs of glucose-lowering agents to guide nurse practitioners in their prescribing patterns for patients with T2D. Conclusion: Patients with T2D are at high risk of CVD, so CV risk should be carefully considered when managing these patients, and CV risks and benefits of antidiabetic drugs should be included in prescribing decisions. Keywords: cardiovascular disease, chronic disease management, type 2 diabetes mellitus, nurse practitioners
first_indexed 2024-03-12T08:44:22Z
format Article
id doaj.art-e201ad0b5d9b4b599fbfa9c4eab0843d
institution Directory Open Access Journal
issn 1178-7007
language English
last_indexed 2024-03-12T08:44:22Z
publishDate 2019-04-01
publisher Dove Medical Press
record_format Article
series Diabetes, Metabolic Syndrome and Obesity
spelling doaj.art-e201ad0b5d9b4b599fbfa9c4eab0843d2023-09-02T16:33:48ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072019-04-01Volume 1244745544914Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trialsHinnen DKruger DFDeborah Hinnen,1 Davida F Kruger2 1Department of Health and Wellness, Memorial Hospital Diabetes Center, University of Colorado Health, Colorado Springs, CO 80909, USA; 2Henry Ford Health System, Division of Endocrinology, Diabetes, Bone and Mineral Disease, Henry Ford Medical Center – New Center One, Detroit, MI 48202, USA Background: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is paramount to determine the relationship between these two diseases. Purpose: Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug Administration published guidance for manufacturers on antihyperglycemic agents, requiring studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents have conducted and published results from CV outcomes trials (CVOTs), with more trials due to publish soon. This review discusses the relationship between CVD and T2D and explores findings from the latest CVOTs of glucose-lowering agents to guide nurse practitioners in their prescribing patterns for patients with T2D. Conclusion: Patients with T2D are at high risk of CVD, so CV risk should be carefully considered when managing these patients, and CV risks and benefits of antidiabetic drugs should be included in prescribing decisions. Keywords: cardiovascular disease, chronic disease management, type 2 diabetes mellitus, nurse practitionershttps://www.dovepress.com/cardiovascular-risks-in-type-2-diabetes-and-the-interpretation-of-card-peer-reviewed-article-DMSOCardiovascular diseasechronic disease managementtype 2 diabetes mellitusnurse practitioners
spellingShingle Hinnen D
Kruger DF
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
Diabetes, Metabolic Syndrome and Obesity
Cardiovascular disease
chronic disease management
type 2 diabetes mellitus
nurse practitioners
title Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_full Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_fullStr Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_full_unstemmed Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_short Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_sort cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
topic Cardiovascular disease
chronic disease management
type 2 diabetes mellitus
nurse practitioners
url https://www.dovepress.com/cardiovascular-risks-in-type-2-diabetes-and-the-interpretation-of-card-peer-reviewed-article-DMSO
work_keys_str_mv AT hinnend cardiovascularrisksintype2diabetesandtheinterpretationofcardiovascularoutcometrials
AT krugerdf cardiovascularrisksintype2diabetesandtheinterpretationofcardiovascularoutcometrials